Timothy J. Craig

1 week ago | ajmc.com | Julia Bonavitacola |Timothy J. Craig

Timothy Craig, DO, professor at Penn State University and principal investigator of the VANGUARD phase 3 trial (NCT04656418) on garadacimab, discussed the safety profile of garadacimab, which was approved for use in patients with hereditary angioedema (HAE) on June 17, and sebetralstat, which is awaiting FDA approval for use as rescue medication in patients with HAE. This transcript has been edited for clarity; captions are auto-generated.

1 week ago | ajmc.com | Julia Bonavitacola |Timothy J. Craig

Timothy Craig, DO, professor at Penn State University and principal investigator of the VANGUARD phase 3 trial (NCT04656418) of garadicamab, believes that garadacimab can be taken in combination with sebetralstat, which is a medication that can offer rescue assistance for patients with hereditary angioedema (HAE). This transcript was edited for clarity; captions are auto-generated. TranscriptAre there differences between garadacimab and sebetralstat when it comes to treating HAE?

1 week ago | ajmc.com | Julia Bonavitacola |Timothy J. Craig

Today, the FDA approved CSL’s garadacimab-gxii (Andembry), a first-in-class factor XII (FXIIa) inhibitor for patients with hereditary angioedema (HAE). Timothy Craig, DO, professor at Penn State University and principal investigator of the VANGUARD phase 3 trial (NCT04656418) on garadacimab, spoke with The American Journal of Managed Care® about what HAE is and how garadacimab works to treat those with the rare disease. This transcript has been edited for clarity; captions were auto-generated.